Segall Bryant & Hamill LLC Has $23.39 Million Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Segall Bryant & Hamill LLC cut its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 149,309 shares of the company’s stock after selling 7,835 shares during the quarter. Segall Bryant & Hamill LLC owned 0.52% of Krystal Biotech worth $23,391,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Entropy Technologies LP acquired a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $548,000. Summit Trail Advisors LLC acquired a new stake in Krystal Biotech during the third quarter worth $1,893,000. Swiss National Bank boosted its stake in Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company’s stock worth $7,117,000 after buying an additional 2,900 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in Krystal Biotech by 42.0% in the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after buying an additional 15,545 shares during the period. Finally, Citigroup Inc. raised its stake in shares of Krystal Biotech by 65.4% in the 3rd quarter. Citigroup Inc. now owns 35,084 shares of the company’s stock valued at $6,386,000 after buying an additional 13,874 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Performance

Shares of KRYS opened at $194.44 on Tuesday. The company has a market cap of $5.60 billion, a price-to-earnings ratio of 65.03 and a beta of 0.87. The stock has a fifty day moving average price of $167.55 and a two-hundred day moving average price of $173.62. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.30 EPS. As a group, research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Activity

In other news, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on KRYS shares. Citigroup lifted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Chardan Capital upped their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright restated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has an average rating of “Buy” and a consensus target price of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).